"Generic versions of this widely used product will offer affordable treatment options for patients who must manage this chronic and potentially serious condition," Gregory Geba, MD, director of the FDA’s Office of Generic Drugs, says in a news release.
Pioglitazone carries a warning about the risk that it may cause or worsen heart failure, and that using pioglitazone for more than one year may be linked to a higher risk of bladder cancer. The FDA recommends careful monitoring of patients when starting the drug or increasing the dosage.
The generic version of pioglitazone is made by Mylan Pharmaceuticals. The FDA states that the generic drugs it approves "are of the same strength and quality" as their brand-name counterparts.